Silence Therapeutics settles patent dispute with Alnylam

UK-based biotech company Silence Therapeutics has settled a patent dispute and entered into a licence agreement with Alnylam Pharmaceuticals.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Silence Therapeutics files SPC case against Alnylam

7 July 2017 Biotech company Silence Therapeutics has filed a case on supplementary protection certificates at the English Patents Court against Alnylam and The Medicines Company.

Big Pharma

Alnylam faces declaratory relief claim over SPCs

20 October 2017 Alnylam Pharmaceuticals and The Medicines Company UK are facing a claim for declaratory relief over supplementary protection certificates requested by biotech company Silence Therapeutics.

Americas

Alnylam says Moderna used patented tech to make vaccine

22 March 2022 Alnylam Pharmaceuticals has accused Moderna of using its nanoparticle technology to develop its COVID-19 vaccine.

More on this story

Europe

Silence Therapeutics files SPC case against Alnylam

7 July 2017 Biotech company Silence Therapeutics has filed a case on supplementary protection certificates at the English Patents Court against Alnylam and The Medicines Company.

Big Pharma

Alnylam faces declaratory relief claim over SPCs

Americas

Alnylam says Moderna used patented tech to make vaccine

22 March 2022 Alnylam Pharmaceuticals has accused Moderna of using its nanoparticle technology to develop its COVID-19 vaccine.

More on this story

Europe

Silence Therapeutics files SPC case against Alnylam

7 July 2017 Biotech company Silence Therapeutics has filed a case on supplementary protection certificates at the English Patents Court against Alnylam and The Medicines Company.

Big Pharma

Alnylam faces declaratory relief claim over SPCs

Americas

Alnylam says Moderna used patented tech to make vaccine

22 March 2022 Alnylam Pharmaceuticals has accused Moderna of using its nanoparticle technology to develop its COVID-19 vaccine.